BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Germany's BioNtech said on Monday it is entering into a partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of its mpox vaccine.

BioNTech partners with CEPI to advance development of mpox vaccine

BioNTech SE BNTX, -0.66% and the Norwegian-based Coalition for Epidemic Preparedness Innovations, or CEPI, said Monday they are partnering to advance an mRNA-based Mpox vaccine. BioNTech will start a Phase 1/2 clinical trial of the vaccine called BNT166, while CEPI will commit funding if up to $90 million for the program.

BioNTech and CEPI to partner to advance an mRNA-based Mpox vaccine

MAINZ, Germany, and OSLO, Norway, September 18, 2023 — BioNTech SE (Nasdaq: BNTX, “BioNTech”, "the Company") and the  Coalition for Epidemic Preparedness Innovations  (CEPI) today announced a strategic partnership to advance mRNA-based vaccine candidates with the development of BNT166 for the prevention of mpox (formerly monkeypox, caused by a member of the Orthopoxvirus viral family), an infectious disease that can lead to severe, life-threatening complications. Mpox gained global attention in May 2022 with an increasing number of cases that then developed into an international outbreak.1,2 CEPI will provide funding of up to $90 million to support the development of mRNA-based vaccine candidates.

BioNTech and CEPI Announce Partnership to Advance mRNA Mpox Vaccine Development and Support CEPI's 100 Days Mission

Recent surges in COVID cases and public interest could drive revenue once again in the near future. However, this renewed attention is also likely to boost investment interest in companies. BioNTech has made significant strides in advancing its pipeline, including advancement with BNT316/ONC-392, a potential treatment for Non-Small Cell Lung cancer that posts a significant market opportunity. Cancer continues to affect a growing population. The BioNTech pipeline holds a variety of candidates addressing these different types, aiming to capture future market share in the multibillion-dollar field of oncology.

BioNTech: Renewed COVID Focus Might Spark Potential Share Price Boost

Moderna

Pfizer

Pfizer (PFE)/ BioNTech (BNTX), and Moderna's (MRNA) updated mRNA vaccines are now approved for individuals 12 years of age and older and are authorized under emergency use for individuals 6 months through 11 years of age.

FDA Approves Pfizer & Moderna's New COVID Booster Vaccines

The updated booster shots arrive as new coronavirus variants circulate.

FDA Approves New Covid Vaccines To Target Latest Strains

The U.S. health regulator on Monday authorized updated COVID-19 vaccines that closely match the Omicron variants that are circulating, starting the process to deploy the shots this month.

US FDA authorizes updated COVID vaccines

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental Biologics License Application (COMIRNATY 2023-2024 Formulation) for individuals 12 years and older and granted emergency use authorization for individuals 6 months through 11 years of age for the companies' Omicron XBB.1.5-adapted monovalent COVID-19 vaccine. This season's vaccine is indicated as a single do.

Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

An updated Covid-19 vaccine made by Pfizer Inc (NYSE:PFE) and BioNTech has been approved by the UK medical regulator, amid a rise in new variants and subvariants of the virus. The new Pfizer-BioNTech vaccine targets the Omicron XBB.1.5 subvariant, which was approved in the European Union last week, was given approved by the UK Medicines & Healthcare products Regulatory Agency (MHRA) on Tuesday, to be given to anyone aged six months or above.

UK joins EU in approving XBB.1.5 jab from Pfizer-BioNTech, but others subvariants are emerging

The UK drug regulator said on Tuesday it has approved an updated COVID-19 vaccine by Pfizer and its German partner BioNTech that targets only the Omicron XBB.1.5 subvariant.

UK regulator approves updated Pfizer-BioNTech COVID vaccine

BioNTech's Q2 2023 revenues significantly decreased due to declining COVID-19 vaccine sales, but the company holds $15.3B in cash reserves. The company's pipeline includes COVID-19 vaccine developments and promising oncology initiatives. The emergence of new COVID-19 variants highlights the potential for ongoing vaccine demand, but public trust and acceptance are crucial.

BioNTech: Not Just Another Jab In The Arm

Pfizer Inc. PFE, -0.25% and BioNTech SE BNTX, +0.58% said Wednesday that its updated COVID-19 vaccine, which is tailored to the new Omicron XBB.1.5 variant has been recommended to receive marketing approval by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). The recommendation is for the updated vaccine to be administered as a single dose to those who are at least five years old, regardless of COVID vaccination history.

Pfizer, BioNTech updated COVID vaccine to treat new variants gets CHMP recommendation use in Europe

NEW YORK and MAINZ, Germany, August 30, 2023 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization for the companies' Omicron XBB.1.5-adapted monovalent COVID-19 vaccine (COMIRNATY® Omicron XBB.1.5) administered as a single dose for individuals 5 years of age and older, regardless of prior COVID-19 vaccination history. The Committee has also recommended the updated vaccine for children 6 months through 4 years of age as part or all of the primary three-dose vaccination series, depending on how many prior doses they received, or as single dose for those with a history of completion of a COVID-19 primary vaccination course or prior SARS-CoV-2 infection.

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union

Novavax

Novavax's hopes in the coronavirus vaccine industry and elsewhere still look shaky. BioNTech has a promising lineup and plenty of cash on hand, but valuation is an issue.

COVID Is Making a Comeback: Should You Buy These 2 Stocks?

Drugmakers like Pfizer and Moderna tamped down expectations. Now, cases are increasing.

Covid Hospitalizations Jump. So Could Vaccine Demand.

Shares of COVID-19 vaccine makers soared after reports suggest that the Biden administration will start a campaign urging citizens to vaccinate themselves with updated shots vaccine in the upcoming fall.

U.S. Govt to Urge Citizens to Get New COVID-19 Shots

Last week, Moderna and BioNTech partner Pfizer said their new COVID vaccines work against the current dominant strain of omicron growing across the U.S. Today, the Biden administration announced a campaign for citizens to get the new boosters this fall.

Why Moderna, BioNTech SE, and Novavax Surged Today

Novavax, Moderna, Pfizer and its partner BioNTech are slated to roll out new shots designed to target the omicron subvariant XBB.1.5 this fall.

Covid vaccine stocks jump as new variants emerge ahead of fall shot rollout

iShares Nasdaq Biotechnology ETF

United Therapeutics

The events of the last few years have made biotech investing look easier than it is. But, investing in biotech is not for the faint of heart.

The 3 Most Undervalued Biotech Stocks to Buy Now: August 2023

MAINZ, Germany, August 14, 2023 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced that the Supervisory Board has appointed James Ryan, Ph.D., to the Management Board as Chief Legal Officer (CLO), effective September 1, 2023. As part of the Management Board, James Ryan will continue to lead the Company's corporate legal strategy and global legal operations including transactions, corporate governance, securities, intellectual property (IP), insurance, data privacy, among others. Prior to his appointment to the Management Board, James Ryan served as the Company's General Counsel and Senior Vice President Legal & IP.

BioNTech Expands Management Board by Appointing James Ryan as Chief Legal Officer

The company fell far short of analyst revenue estimates in its latest-reported quarter. It also flipped to a loss on the bottom line.

Why BioNTech Stock Was Sinking Today

BioNTech SE (NASDAQ:BNTX ) Q2 2023 Earnings Conference Call August 7, 2023 8:00 AM ET Company Participants Victoria Meissner - VP, Strategy & IR Ugur Sahin - Co-Founder & CFO Ozlem Tureci - Chief Medical Officer & Co-Founder Jens Holstein - CFO Ryan Richardson - Chief Strategy Officer Conference Call Participants Daina Graybosch - Leerink Partners Tazeen Ahmad - Bank of America Chris Shibutani - Goldman Sachs Brendan Smith - TD Cowen Terence Flynn - Morgan Stanley Bill Maughan - Canaccord Simon Baker - Redburn Operator Welcome to BioNTech's Second Quarter 2023 Update Call. I would like to hand the call over to Dr. Victoria Meissner, Vice President of Strategy and Investor Relations.

BioNTech SE (BNTX) Q2 2023 Earnings Call Transcript

American Depositary Receipts of BioNTech sank as COVID-19 vaccine demand waned and sales of its vaccine plunged.

BioNTech Revenue Plunges on Falling Demand for COVID-19 Vaccines

BioNTech SE (NASDAQ:BNTX) is sinking to two-year lows today, after plunging Covid vaccine sales weighed on the company's second-quarter results.

Biotech Stock Hits 2-Year Low as Vaccine Sales Decline

BioNTech reported lighter-than-expected second-quarter sales on Monday, though kept its sales outlook for the year. BNTX stock plunged.

News for BioNTech SE Stock (BNTX)